Noile-Immune Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Noile-Immune Biotech has a total shareholder equity of ¥5.0B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥5.1B and ¥82.0M respectively.
Key information
0%
Debt to equity ratio
JP¥0
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥4.95b |
| Equity | JP¥5.01b |
| Total liabilities | JP¥82.00m |
| Total assets | JP¥5.09b |
Financial Position Analysis
Short Term Liabilities: 4893's short term assets (¥5.1B) exceed its short term liabilities (¥76.0M).
Long Term Liabilities: 4893's short term assets (¥5.1B) exceed its long term liabilities (¥6.0M).
Debt to Equity History and Analysis
Debt Level: 4893 is debt free.
Reducing Debt: 4893 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4893 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4893 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.1% each year